Form 4: Phathom Pharmaceuticals Director Frank Karbe Acquires 12,500 Shares

Director Frank Karbe of Phathom Pharmaceuticals purchased 12,500 shares of common stock at a weighted average price of $7.9267 on December 13, 2024.

Summary

• Frank Karbe, a director at Phathom Pharmaceuticals, acquired 12,500 shares of the company's common stock on December 13, 2024.
• The shares were purchased at a weighted average price of $7.9267 per share.
• The transactions occurred at prices ranging from $7.87 to $8.00.
• Following the transaction, Mr. Karbe directly owns 57,000 shares of Phathom Pharmaceuticals.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction. While the purchase is a positive signal, it's not a major event that would significantly impact sentiment.

Positives

• The purchase of shares by a director can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider trading.
• The transaction is typical for directors who may acquire shares as part of their compensation or personal investment strategies.
• The price range of $7.87 to $8.00 is within the normal trading range for the stock at the time of the transaction.

Stakeholder Impact

• The share purchase by a director may be viewed positively by shareholders, indicating confidence in the company's prospects.

Key Dates

Keywords

Phathom Pharmaceuticals, Frank Karbe, insider trading, share purchase, common stock, director